Eris Lifesciences Ltd
NSE:ERIS

Watchlist Manager
Eris Lifesciences Ltd Logo
Eris Lifesciences Ltd
NSE:ERIS
Watchlist
Price: 1 533.9 INR -1.15% Market Closed
Market Cap: 208.9B INR

Eris Lifesciences Ltd
Pre-Tax Income

Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Last Value
3 Years 3Y CAGR
5 Years 5Y CAGR
10 Years 10Y CAGR
Quarterly
Annual
TTM
|
See Also

Eris Lifesciences Ltd
Pre-Tax Income Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Pre-Tax Income CAGR 3Y CAGR 5Y CAGR 10Y
Eris Lifesciences Ltd
NSE:ERIS
Pre-Tax Income
₹5.8B
CAGR 3-Years
12%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Dr Reddy's Laboratories Ltd
NSE:DRREDDY
Pre-Tax Income
₹75.3B
CAGR 3-Years
20%
CAGR 5-Years
30%
CAGR 10-Years
15%
Cipla Ltd
NSE:CIPLA
Pre-Tax Income
₹70.4B
CAGR 3-Years
25%
CAGR 5-Years
22%
CAGR 10-Years
12%
Sun Pharmaceutical Industries Ltd
NSE:SUNPHARMA
Pre-Tax Income
₹140.7B
CAGR 3-Years
40%
CAGR 5-Years
53%
CAGR 10-Years
11%
Lupin Ltd
NSE:LUPIN
Pre-Tax Income
₹53.9B
CAGR 3-Years
164%
CAGR 5-Years
39%
CAGR 10-Years
6%
T
Torrent Pharmaceuticals Ltd
NSE:TORNTPHARM
Pre-Tax Income
₹28.8B
CAGR 3-Years
32%
CAGR 5-Years
16%
CAGR 10-Years
4%
No Stocks Found

Eris Lifesciences Ltd
Glance View

Market Cap
208.9B INR
Industry
Pharmaceuticals

Nestled in the competitive landscape of India's pharmaceutical sector, Eris Lifesciences Ltd. has carved a niche for itself by focusing intently on the domestic market, predominantly within the specialty prescription segment. Founded in 2007 by Amit Bakshi, the company has distinguished itself with a strategy that emphasizes building relationships with medical professionals through a robust field force, eschewing the conventional tactic of overwhelming physicians with a vast army of generic products. Eris opts for precision, targeting chronic and lifestyle-related ailments such as diabetes, cardiology, and neurology. This focus on long-term therapies aligns with the rising demand for healthcare tailored to the aging population's needs and the increase in lifestyle diseases in India, thus ensuring a steady stream of revenue. The brilliance of Eris Lifesciences' business model is reflected in its comprehensive distribution network and a well-coordinated supply chain that covers a significant portion of Indian urban centers. By manufacturing many of its products in-house, Eris maintains control over production quality and cost – a strategic move that bolsters its pricing power in the competitive generics market. The company also adeptly tweaks its offerings and strategies based on physician feedback and market trends, ensuring relevance and resonance with its target segments. This model is not about flooding the market with a plethora of offerings; it's about precision placement with specialized therapeutic products that meet specific, high-demand needs – a strategy that has consistently translated into tangible financial growth.

ERIS Intrinsic Value
1 352.56 INR
Overvaluation 12%
Intrinsic Value
Price

See Also

What is Eris Lifesciences Ltd's Pre-Tax Income?
Pre-Tax Income
5.8B INR

Based on the financial report for Sep 30, 2025, Eris Lifesciences Ltd's Pre-Tax Income amounts to 5.8B INR.

What is Eris Lifesciences Ltd's Pre-Tax Income growth rate?
Pre-Tax Income CAGR 5Y
11%

Over the last year, the Pre-Tax Income growth was 32%. The average annual Pre-Tax Income growth rates for Eris Lifesciences Ltd have been 12% over the past three years , 11% over the past five years .

Back to Top